Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.39 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.38 |
| ▸ | ALKBH2 | Q6NS38 | 1/20 | 0.37 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.37 |
| ▸ | ALKBH3 | Q96Q83 | 1/20 | 0.37 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.37 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.36 |
| ▸ | RET | P07949 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.36 |
| ▸ | PKMYT1 | Q99640 | 1/20 | 0.36 |
| ▸ | KDM5A | P29375 | 1/20 | 0.36 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.36 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.36 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.36 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.35 |
| ▸ | G6PD | P11413 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5700255 | 0.82 | ALDH1A1 (0.46) | LMNAPIK3C3ENPP2ALKBH2ALKBH5 | |
| SCHEMBL30525023 | 0.82 | KDM4E (0.53) | LMNAPIK3C3ENPP2ALKBH2ALKBH5 | |
| SCHEMBL20790368 | 0.82 | KDM4E (0.53) | LMNAPIK3C3ENPP2ALKBH2ALKBH5 | |
| SCHEMBL30874237 | 0.81 | ADORA3 (0.40) | LMNAPIK3C3KDM5AKDM4CKDM5B | |
| SCHEMBL6742155 | 0.78 | ALDH1A1 (0.40) | LMNAPIK3C3ALKBH5FTORIPK2 | |
| SCHEMBL20791437 | 0.78 | ALDH1A1 (0.50) | LMNAPIK3C3KDM4C | |
| SCHEMBL5700227 | 0.77 | HRH4 (0.41) | LMNAPIK3C3ENPP2RIPK2RET | |
| Lithium Ion SCHEMBL19065619 | 0.76 | PIK3C3 (0.62) | PIK3C3 | |
| SCHEMBL6742993 | 0.76 | KMT2A (0.53) | ALKBH2ALKBH5FTOKDM5BAKR1C2 | |
| SCHEMBL5700236 | 0.72 | MAPT (0.45) | ALKBH2ALKBH5FTOPTGDR2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113453764-B | 7H-pyrrolo [2,3-d ] pyrimidin-4-amine derivatives | 大鹏药品工业株式会社 | 2024-04-16 | — | — | CN | disclosed |
| US-11786534-B2 | Substituted pyrrolo[2,3-d]pyrimidines as EGFR inhibitors | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2023-10-17 | — | — | US | disclosed |
| US-20220160719-A1 | 7H-PYRROLO[2,3-D]PYRIMIDINE-4-AMINE DERIVATIVE | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2022-05-26 | — | — | US | disclosed |
| EP-3925669-A1 | 7H-PYRROLO[2,3-D]PYRIMIDINE-4-AMINE DERIVATIVE | Taiho Pharmaceutical Co., Ltd. (JP) | 2021-12-22 | — | — | EP | disclosed |
| CN-113453764-A | 7H-pyrrolo [2,3-d ] pyrimidin-4-amine derivatives | 大鹏药品工业株式会社 | 2021-09-28 | — | — | CN | disclosed |
| WO-2020166680-A1 | 7H-PYRROLO[2,3-D]PYRIMIDINE-4-AMINE DERIVATIVE | 大鵬薬品工業株式会社 | 2020-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220160719-A1 | 7H-PYRROLO[2,3-D]PYRIMIDINE-4-AMINE DERIVATIVE | EGFR, ERBB2, ERBB4 | LMNA 4881/4885PIK3C3 244/4885ENPP2 3730/4885 |
| US-11786534-B2 | Substituted pyrrolo[2,3-d]pyrimidines as EGFR inhibitors | EGFR, ERBB2, ERBB3 | LMNA 4883/4885PIK3C3 148/4885ENPP2 3395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.